U.S. Markets open in 4 hrs 12 mins

Bernd Liesenfeld, the President of Quick-Med Technologies, Inc. (QMDT), Interviews with The Wall Street Transcript

67 WALL STREET, New York - April 25, 2014 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Orphan Drug and Biologics Manufacturing - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Biotechnology and Pharmaceutical Companies Valuation - Genetic and Cell Therapies

Companies include: Quick-Med Technologies, Inc. (QMDT) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, the President of Quick-Med Technologies, Inc. (QMDT) discusses company strategy and the outlook for this vital industry:

TWST: Could you talk about about your recent license deals for Stay Fresh with Medline and Sarasota Medical Products?

Dr. Liesenfeld: The Stay Fresh technology allows us to sequester hydrogen peroxide; you know hydrogen peroxide from being a common over-the-counter disinfectant and also for color-safe bleaching. The liquid is unstable, and if you apply and leave it on something, it just evaporates away. What we've developed are several chemistries to sequester the hydrogen peroxide into various matrix products. In one incarnation, we use a metal oxide particle as the matrix, and in another case, we use a superabsorbent. The latter of those, the superabsorbent, is what we have licensed to Sarasota Medical Products.

Sarasota Medical Products really fits the profile for a great partner. They are a highly expert manufacturer in the field that has a defined need within their segment, which is to add the antimicrobial feature to their product. They are able to engage directly with us on a technical and developmental level, and have direct access to the distribution channels in order to make the products a success in the marketplace.

What they make are hydrocolloids. Hydrocolloids have two broad classes of use. One is as a wound dressing for mildly exudating wounds, including diabetic ulcers or pressure ulcers. Another is for ostomy applications. The ostomy applications are a slightly larger market; the overall figures are in the low billions of dollars for the U.S. and significantly higher globally. They already have a superabsorbent in their formulation, so the advantage of utilizing the Stay Fresh superabsorbent technology is that it adds antimicrobial efficacy to their hydrocolloid formulation, but without changing the production process. That gives them the opportunity to put forward a technology that doesn't have a direct equivalent in the marketplace.

The hydrocolloids marketplace has seen some activity with antimicrobials, mainly silvers that made the product so much more expensive that they were uneconomical to utilize, and we've seen several of those withdrawn from the marketplace in the recent time. We help Sarasota to position its offering as an economical implementation of an antimicrobial hydrocolloid that is going to be a great aid in infection prevention and control strategies, both for wound dressings - mainly targeting pressure ulcer and diabetic ulcer sufferers - and also for ostomy applications, where there is clear need for hygiene support.

TWST: When do you expect that product to be commercialized?

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.